NSAIDs and the risk of CV events: is there a class effect?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1492, 2005-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatotoxicity with Thiazolidinediones: Is it a Class Effect?

By Scheen A.J.

Drug Safety, Vol. 24, Iss. 12, 2001-01 ,pp. : 873-888

Adis International

Access to resources Recommend Favorite

COX-2 inhibitors: increased risk of CV events?

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Sleep Attacks or Unintended Sleep Episodes Occur with Dopamine Agonists: Is This a Class Effect?

By Chaudhuri K.R.

Drug Safety, Vol. 25, Iss. 7, 2002-01 ,pp. : 473-483

Adis International

Access to resources Recommend Favorite

Inhaled anticholinergics: increased risk of major adverse CV events?

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Intra-articular hyaluronan in OA: mostly placebo effect?

Inpharma, Vol. 1, Iss. 1419, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite